B+
Bull case
20%
Probability
Target price
$2.75
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
AARD
Aardvark TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Removal of the clinical hold restores a possible development path, and exploratory HERO/OLE signals could help shape a viable lower-dose trial. Neither regulatory clearance to resume nor the partial dataset proves efficacy.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +23.7.
What can break
A replacement trial may consume cash faster than the operating plan underlying the June 2026 late-2027 runway estimate.
Momentum
91
Value
57
Sentiment
67
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.45 · Bull $2.75 · Bear $0.55Analysis 2026-10-24; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-24 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-27
Investment thesis
As of 2026-10-27
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $7.50
Why
Momentum91 · Δ7d -5.3
Value57 · Δ7d +16.6
Sentiment67 · Δ7d +23.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +23.7.
Contradictions & invalidation
- • A replacement trial may consume cash faster than the operating plan underlying the June 2026 late-2027 runway estimate.
- • Cardiac and drug-interaction findings could constrain dosing or require further safety work.
- • HERO was terminated early, its efficacy findings are exploratory, and a new Phase 3 trial introduces time, execution, safety and funding risk.
Catalyst clock
2026-11-06
Market reassessment of exploratory HERO/OLE data
Lead driver: Sentiment · See AI snapshot
Momentum
91
8% active weight
Current posture
7d trendSoftening
Δ7d
-5.3
Δ21d
-
Value
57
47% active weight
Current posture
7d trendImproving
Δ7d
+16.6
Δ21d
+16.4
Sentiment
67
45% active weight
Current posture
7d trendImproving
Δ7d
+23.7
Δ21d
-
Why this grade
Composite grade A. Momentum 91.2 / Value 57.4 / Sentiment 67.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-24. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$1.45
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.55
Analysis reference price unavailable
Analysis 2026-10-24 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$28.45M
Beta
-
Shares Out
21.88M
P/E (TTM) · Derived
-0.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.41
Rev YoY
-
EPS YoY
-0.6%
Gross Margin
-
Op Margin
-
Net Debt
-$109.59M
Current Ratio
12.63
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data